Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.10.22	Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022 (PR Newswire)
03.10.22	Regeneron Elects Dr. Craig B. Thompson to Board of Directors (PR Newswire)
30.09.22	Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO (PR Newswire)
29.09.22	Sanofi-Aktie dennoch schwach: US-Gesundheitsbehörde FDA verkündet Zulassung von Sanofi/Regeneron-Hautmedikament (Dow Jones) Die US-Gesundheitsbehörde FDA hat das Medikament Dupixent von Sanofi und Regeneron Pharmaceuticals zur Behandlung von Patienten mit der seltenen Hautkrankheit Prurigo nodularis zugelassen.» mehr
29.09.22	Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment (RTTNews)
28.09.22	Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis (PR Newswire)
16.09.22	Intellia: Interim Data Show NTLA-2001 Can Profoundly Reduce Serum TTR Levels (RTTNews)
16.09.22	Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis (PR Newswire)
16.09.22	Positive Dupixent® (dupilumab) Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Published in The Lancet (PR Newswire)
15.09.22	Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers (PR Newswire)
12.09.22	Positive Neoadjuvant Libtayo® (cemiplimab) Monotherapy Data in Resectable Cutaneous Squamous Cell Carcinoma Presented at ESMO and Published in NEJM (PR Newswire)
12.09.22	Regeneron: Fianlimab With Libtayo Shows Greater Than 60% Response Rates In Phase 1 Trial (RTTNews)
12.09.22	Fianlimab (LAG-3 Inhibitor) Combined with Libtayo® (cemiplimab) Demonstrates Greater than 60% Response Rates in Two Independent Cohorts of Patients with Advanced Melanoma Naïve to PD-1 or PD-L1 In... (PR Newswire)
10.09.22	Novel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors (PR Newswire)
09.09.22	Regeneron Announces Investor Call and Webcast at ESMO 2022 (PR Newswire)
08.09.22	Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis (PR Newswire)
08.09.22	Bayer erreicht Studienziel mit Augenmittel - Wichtig im Konkurrenzkampf (AWP)
08.09.22	Regeneron: Aflibercept 8 Mg Meets Primary Endpoints In Two Trials For DME And WAMD (RTTNews)
08.09.22	Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals (PR Newswire)
05.09.22	Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma (PR Newswire)
05.09.22	Sanofi: Dupixent Data Show Sustained Improvement For Up To 2 Yrs In 6-11 Years With Asthma (RTTNews)
05.09.22	ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers (PR Newswire)
29.08.22	Alnylam: Additional Data Shows Favorable Effects Of Cemdisiran On Different Measures Of proteinuria (RTTNews)
27.08.22	Biotech Stocks Facing FDA Decision In September (RTTNews)
25.08.22	Regeneron Announces Investor Conference Presentations (PR Newswire)
03.08.22	Regeneron Q2 Profit Down On Weak Revenues; Revises FY22 Margin, R&D Outlook (RTTNews)
03.08.22	Regeneron's REGN5678 Shows Encouraging Anti-tumor Activity When Combined With Libtayo (RTTNews)
03.08.22	Regeneron Reports Second Quarter 2022 Financial and Operating Results (PR Newswire)
03.08.22	Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (m... (PR Newswire)
02.08.22	Ausblick: Regeneron Pharmaceuticals präsentiert Bilanzzahlen zum jüngsten Jahresviertel (finanzen.net)
27.07.22	Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease (PR Newswire)
26.07.22	Regeneron Announces the 2022 Winners of the Regeneron Prize for Creative Innovation (PR Newswire)
19.07.22	Erste Schätzungen: Regeneron Pharmaceuticals stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
14.07.22	Regeneron: Phase 3 Trial Of Dupixent In Children With Eosinophilic Esophagitis Meets Main Goal (RTTNews)
14.07.22	Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (PR Newswire)
12.07.22	Ultima Genomics signs development agreement with Regeneron aimed at driving the scale of genomic information for drug discovery and development (PR Newswire)
06.07.22	Regeneron to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2022 (PR Newswire)
01.07.22	Regeneron Completes Acquiring Sanofi's Stake In Libtayo (RTTNews)
01.07.22	Regeneron Completes Purchase of Sanofi's Stake in Libtayo® (cemiplimab) (PR Newswire)
29.06.22	Regeneron's EYLEA SBLA For 16-week Dosing Regimen In Diabetic Retinopathy Accepted For FDA Review (RTTNews)
29.06.22	EYLEA® (aflibercept) Injection sBLA for Every 16-week Dosing Regimen in Patients with Diabetic Retinopathy Accepted for FDA Review (PR Newswire)
28.06.22	Biotech Stocks Facing FDA Decision In July 2022 (RTTNews)
24.06.22	NTLA : Study Of NTLA-2001 On Transthyretin Amyloidosis Shows Serum TTR Reductions Remained Durable (RTTNews)
24.06.22	Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions ... (PR Newswire)
09.06.22	Alnylam Pharma Reports Positive Topline Results From Phase 2 Study Of Cemdisiran (RTTNews)
08.06.22	Sanofi : FDA Approves Dupixent For Young Children With Moderate-to-severe Atopic Dermatitis (RTTNews)
07.06.22	FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis (PR Newswire)
02.06.22	Sanofi- und Regeneron-Aktien schwächer: Regeneron zahlt Sanofi für Anteil an Krebsmedikament Libtayo Millionenbetrag (Dow Jones) Regeneron Pharmaceuticals übernimmt den Anteil seines Partners Sanofi am Anti-PD-1-Krebsmedikament Libtayo.» mehr
02.06.22	Regeneron To Acquire Global Rights To Libtayo From Sanofi For $900 Mln, Plus Royalties (RTTNews)
02.06.22	Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of ... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus